Companies · Pharmaceuticals

Strive Pharmacy Utah I LLC

GILBERT · Pharmaceuticals

Diligence memoA one-page analyst read on Strive Pharmacy Utah I LLC — recommendation, valuation, rhythm, risks.
$298K
Total raised · real
1
Rounds
0.3×
Latest step-up
Top 94%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Strive Pharmacy Utah I LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.05× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
  • Within the normal band (105% of peer median) for its niche.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Strive Pharmacy Utah I LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
7.0 yr record
Peak capital year was 2019 with $400K across 2 filings.
Market position
ahead of 7% of Pharmaceuticals peers
Capital scale is ahead of 7% of Pharmaceuticals peers; modeled value is above 22% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2019: $400K across 2 filings.
  • Largest single filing was $298K on 2019-07-16.
  • Filing rows sum to $400K, while canonical raised total is $298K; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Strive Pharmacy Utah I LLC is one of 1613 Pharmaceuticals companies tracked from GILBERT. By capital raised it ranks in the long tail (ahead of 7% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 504
Reg D exemption
4
Investors (latest)
2019
Year incorporated
2019-07-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2019-07-16 Raised $298K (real) Modeled valuation $14M (est)$298K$14MPre-Seed2019Pre-Seed · 2019-07-16 Raised $103K (real) Modeled valuation $4.9M (est)$103K$4.9MPre-Seed2019+$103KCumulative $400K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$298K · 2019
Pre-Seed extension$103K · 2019

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$14.1M
Base estimate est.
$167K
Conservative case
$159.6M
Upside case
$1.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $14.1M · 2019-07-162019Pre-Seed · modeled $4.9M · 2019-07-162019
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
7.0 yr
On record since
2019
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$298K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.2× of median
This company$103K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$14.1M
Sector median$76.1M

Raised more than 7% of sector peers (real $). Modeled value above 22% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #22 of 46.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Elion Oncology, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Cyclone Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Sonnet Biotherapeutics, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Fastball Capital Group, Llc · Pre-Seed Raised $750K · modeled $35.5M (est)TamRx, LLC · Pre-Seed Raised $700K · modeled $33.1M (est)Veana Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $32.9M (est)Ariz Precision Medicine, Inc. · Pre-Seed Raised $685K · modeled $32.4M (est)Vascarta Inc. · Pre-Seed Raised $649K · modeled $28.1M (est)Enfuego Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $27.0M (est)Sincerus Pharmaceuticals Inc · Pre-Seed Raised $506K · modeled $23.9M (est)Neurodon Corp · Pre-Seed Raised $500K · modeled $23.7M (est)Elite Pharmaceuticals Inc /Nv/ · Pre-Seed Raised $3.3M · modeled $23.4M (est)Strive Pharmacy Utah I LLC (this company) Raised $298K · modeled $14.1M (est)Strive Pharmacy Utah I LLC
CompanyStageRaised · realValue · estvs peer med.
Elion Oncology, Inc.Pre-Seed$1.0M$47.3M3.54×
Cyclone Therapeutics, Inc.Pre-Seed$800K$37.8M2.83×
Sonnet Biotherapeutics, Inc.Pre-Seed$750K$35.5M2.66×
Fastball Capital Group, LlcPre-Seed$750K$35.5M2.66×
TamRx, LLCPre-Seed$700K$33.1M2.48×
Veana Therapeutics, Inc.Pre-Seed$1.4M$32.9M2.46×
Ariz Precision Medicine, Inc.Pre-Seed$685K$32.4M2.43×
Vascarta Inc.Pre-Seed$649K$28.1M2.10×
Enfuego Therapeutics, Inc.Pre-Seed$1.0M$27.0M2.02×
Sincerus Pharmaceuticals IncPre-Seed$506K$23.9M1.79×
Neurodon CorpPre-Seed$500K$23.7M1.77×
Elite Pharmaceuticals Inc /Nv/Pre-Seed$3.3M$23.4M1.75×
Strive Pharmacy Utah I LLC this companyPre-Seed$298K$14.1M1.05×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$298K2019-07-16$1.7M$14.1M90%
Pre-Seed$103K2019-07-16$570K$4.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$298K2019-07-16
    • First recorded raise — entered as Pre-Seed.
    • 14 investors on this round.
  2. Pre-Seed$103K2019-07-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.9× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
Modeled next raise
$103K
Modeled next size est.range $103K$164K
0.3×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Mike Walker1 other2019-07
Nathan Hill2019-07
Registry & provenance

Strive Pharmacy Utah I LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1784544
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
FHKA Holdings LLCPharmaceuticalsPre-Seed$300K$8.3Msame sector · same stage
Kadmus Pharmaceuticals IncPharmaceuticalsPre-Seed$300K$14.2Msame sector · same stage
Midway Pharmaceuticals IncPharmaceuticalsPre-Seed$300K$14.2Msame sector · same stage
OncoTelic Inc.PharmaceuticalsPre-Seed$300K$14.2Msame sector · same stage
Peptivir, Inc.PharmaceuticalsPre-Seed$300K$14.2Msame sector · same stage
Occam Sciences, Inc.PharmaceuticalsPre-Seed$300K$14.2Msame sector · same stage
Gr Biosystems, IncPharmaceuticalsPre-Seed$295K$12.0Msame sector · same stage
Network Life Sciences Inc.PharmaceuticalsPre-Seed$310K$14.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Strive Orthopedics, Inc.BiotechnologyPre-Seed$27.6M75%
Milestone Pharmaceuticals Inc.PharmaceuticalsSeries C$2.8B75%
Bell Pharmacy Holdings, LLCPharmaceuticalsPre-Seed$2.2M75%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B74%
Matchpoint Therapeutics Inc.PharmaceuticalsSeries C$672.3M74%
Emerald Health Pharmaceuticals Inc.PharmaceuticalsSeed$6.9M74%
Galenus Precision Pharmacy, Inc.PharmaceuticalsSeries A$13.6M74%
Lamassu Pharma, LLCPharmaceuticalsSeed$101.5M74%
Frequently asked
How much funding has Strive Pharmacy Utah I LLC raised?
Strive Pharmacy Utah I LLC has raised approximately $298K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Strive Pharmacy Utah I LLC's estimated valuation?
Provath's modeled valuation for Strive Pharmacy Utah I LLC is approximately $14.1M (modeled range $167K–$159.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Strive Pharmacy Utah I LLC at?
Strive Pharmacy Utah I LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Jul 16.
What does Strive Pharmacy Utah I LLC do and where is it based?
Strive Pharmacy Utah I LLC operates in the Pharmaceuticals sector, based in GILBERT.
Explore related

See where Strive Pharmacy Utah I LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Strive Pharmacy Utah I LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.